Small Cell Lung Cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies And Key Companies Involved by DelveInsight | Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Lab , Amgen , Bristol Myers, Pfizer , Xencor , ABBVIE , Sorrento ...

 

2039 STUDIES FOUND FOR : SMALL CELL LUNG CÁNCER .

El Informe Small Cell Lung Cancer Pipeline Abarca una Evaluación Clínica y Comercial en Profundidad de los Productos de la Tubería Desde la Fase de Desarrollo Preclínico Hasta la Fase de Comercialización .

Some of The Key Takeaways From The Small Cell Lung Cancer Pipeline Report :

• 
  Companies across the globe are diligently working toward developing novel Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years .
• Small Cell Lung Cancer companies working in the treatment market are Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, Akeso, Ascentage Pharma, BioNTech, Qilu Pharmaceutical Co, Amgen, BeiGene, Sorrento Therapeutics, and others, are developing therapies for the Small Cell Lung Cancer treatment .
• Emerging Small Cell Lung Cancer therapies such as - RP12146, SYHA 1807, AK104, APG 1252, BNT 411, QL1706, Tarlatamab, Tislelizumab, Socazolimab, and others are expected to have a significant impact on the Small Cell Lung Cancer market in the coming years .

• 
  In March 2022, The FDA has designated HPN328, a delta-like ligand 3- (DLL3) targeting TriTAC®, as an orphan drug for the treatment of small-cell lung cancer (SCLC), according to a statement from Harpoon Therapeutics, Inc. HPN328 is presently the subject of a Phase 1/2 clinical investigation in SCLC patients .

• In March 2022, Akeso, Inc. announced that it has partnered with Shenzhen Chipscreen Biosciences, Ltd. (SHA Code 688321) to conduct a Phase Ib/II clinical trial of combination therapy using the highly selective Aurora B/VEGFR/PDGFR/c-Kit/CSF1R inhibitor Chiauranib and Cadonilimab in patients with ES-SCLC who progressed on combination therapy using platinum-based chemotherapy and PD-(L)1 .

• In July 2021, Patients with untreated advanced stage Small Cell Lung Cancer were enrolled in a Phase III, randomised, double-blind, placebo-controlled research of Carboplatin Plus Etoposide with or without ZKAB001 (Anti-PD-L1 Antibody) .